Literature DB >> 26422844

Bilateral sympathicotomy for hyperhidrosis without using single-lung ventilation.

Tevfik Kaplan, Perihan Ekmekçi, Bülent Koçer, Serdar Han.   

Abstract

BACKGROUND/AIM: The goal of this retrospective study was to evaluate the outcomes and complications of bilateral videothoracoscopic sympathicotomy without using single-lung ventilation in the treatment of primary hyperhidrosis and facial blushing.
MATERIALS AND METHODS: We retrospectively reviewed 154 consecutive patients (70 females and 84 males) who underwent bilateral sympathicotomy for palmar, axillary, and facial/scalp hyperhidrosis or facial blushing from February 2005 to June 2013. The patients were intubated with single-lumen endotracheal tube, and then sympathicotomies were performed via videothoracoscopy during controlled apnea periods.
RESULTS: Sympathicotomies were performed at costal levels 2, 3, and 4. No perioperative mortality or conversion to open surgery was recorded. Mean operation time was 31.2 ± 2.4 min and mean hospital stay was 1.1 ± 0.6 days. One patient experienced a unilateral pneumothorax that required treatment. There were no abnormal hemodynamic parameters measured during the perioperative apnea periods. The long term follow-up period was 21.4 ± 5 months. Twenty-nine cases (18.8%) were complicated by compensatory sweating. No recurrence was observed during the follow-up period.
CONCLUSION: Video-assisted thoracoscopic sympathicotomy without lung isolation provides effective cure of primary hyperhidrosis and facial blushing. This procedure can shorten the operative time without any aberrant hemodynamic shifts.

Entities:  

Mesh:

Year:  2015        PMID: 26422844     DOI: 10.3906/sag-1405-51

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  1 in total

1.  Comparison of T2 and T3 sympathectomy for compensatory sweating on palmar hyperhidrosis.

Authors:  Atila Turkyilmaz; Sami Karapolat; Kubra Nur Seyis; Celal Tekinbas
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.